U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-QSB/A Amendment No. 1

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 1998

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from _____to____.

Commission File Number 0-21221

MICROVISION, INC. (Exact Name of Small Business Issuer as Specified in Its Charter)

Washington91-1600822(State or Other Jurisdiction of
Incorporation or organization)(I.R.S. Employer Identification No.)

2203 Airport Way South, Suite 100, Seattle, Washington 98134 (Address of Principal Executive Offices)

Issuer's telephone number, including area code: (206) 623-7055

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No []

As of June 30, 1998, 6,006,826 shares of the Company's common stock, no par value, were outstanding.

Transitional Small Business Disclosure Format: Yes [] No [X]

PART I FINANCIAL INFORMATION

	Page
Item 1 - Financial Statements Balance Sheet at June 30, 1998 and December 31, 1997	3
Statement of Operations for the three and six months ended June 30, 1998 and 1997	4
Statement of Cash Flows for the six months ended June 30, 1998 and 1997	5
Statement of Comprehensive Income for the three months and six months ended June 30, 1998 and 1997	6
Notes to Financial Statements	7
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	8

2

<TABLE> <CAPTION>

MICROVISION, INC.

Balance Sheet

	June 30, 1998	December 31, 1997
<s></s>	<c></c>	<c></c>
ASSETS		
Current assets		
Cash and cash equivalents	\$ 4,085,800	\$ 5,049,200
Investment securities available-for-sale	1,795,300	3,792,000
Accounts receivable, net	1,330,900	150,000
Costs and estimated earnings in excess of		
billings on uncompleted contracts	734,300	843,800
Other current assets	80,600	113,100
Total current assets	8,026,900	9,948,100
Property and equipment, net	1,327,100	772,700
Other assets	44,100	20,000

	\$ 9,398,100	\$ 10,740,800
LIABILITIES AND SHAREHOLDERS' EOUITY		
Current liabilities		
Accounts payable	\$ 1,235,300	\$ 768,200
Accrued liabilities	1,305,500	715,900
Billings in excess of costs and estimated earnings		
on uncompleted contracts	251,900	-
Current portion of capital lease obligations	85,000	22,700
Total current liabilities	2,877,700	1,506,800
Capital lease obligations, net of current portion	224,300	69,600
Shareholders' Equity		
Common stock	25,553,300	25,375,300
Deferred compensation	(384,300)	(701,200)
Unrealized holding loss on investment securities	(4,700)	(1,200)
Accumulated deficit	(18,868,200)	(15,508,500)
Total shareholders' equity	6,296,100	9,164,400
iotal bhalcholacib equity		
	\$ 9,398,100	\$ 10,740,800

See accompanying notes to financial statements.

</TABLE>

3

<TABLE> <CAPTION>

MICROVISION, INC.

Statement of Operations

June 30,		Ended June 30,	Six Months 1	
1997	1998	1997	1998	
<s> Contract revenue 102,200</s>	<c> \$ 2,055,900</c>	<c> \$ 102,200</c>	<c> \$ 3,764,100</c>	<c> \$</c>
Research and development expense 1,583,400 Marketing, general and	2,926,500	933,700	4,785,800	
administrative expense 1,407,200	1,345,800	726,900	2,514,600	
Total expenses 2,990,600	4,272,300	1,660,600	7,300,400	
Loss from operations (2,888,400)	(2,216,400)	(1,558,400)	(3,536,300)	
Other income 222,500	-	222,500	-	
Interest income 333,100	82,100	161,100	189,500	
Interest expense (1,300)	(8,900)	(600)	(12,900)	
Net loss (2,334,100)	\$ (2,143,200)	\$ (1,175,400)	\$ (3,359,700)	90 10

Net loss per share (0.40)	\$ (0.36)	\$ (0.20)	\$ (0.56)	Ş
Weighted average shares outstanding 5,780,600	5,964,700	5,782,200	5,954,900	
Net loss per share assuming dilution (0.40)	\$ (0.36)	\$ (0.20)	\$ (0.56)	Ş
======				
Weighted average shares outstanding assuming dilution 5,780,600	5,964,700	5,782,200	5,954,900	
-,,				

See accompanying notes to financial statements.

</TABLE>

4

<TABLE>

<CAPTION>

MICROVISION, INC.

Statement of Cash Flows

	Six Months Ended June 30,	
	1998	1997
<s></s>	<c></c>	<c></c>
Cash flows from operating activities Net loss Adjustments to net cash used in operations:	\$ (3,359,700)	\$ (2,334,100)
Depreciation and write-off of fixed assets Non-cash expenses related to issuance of stock,	207,200	45,900
warrants and options and deferred compensation	317,700	49,900
Unrealized holding loss on investment securities Changes in:	(3,500)	-
Accounts receivable	(1,180,900)	(49,300)
Costs and expenses in excess of billings	109,500	-
Other current assets	32,500	(48,700)
Other assets	(24,100)	18,000
Accounts payable Accrued liabilities	467,100 589,600	12,000 (288,000)
Billings in excess of costs and expenses	251,900	(288,000)
Net cash used in operating activities	(2,592,700)	(2,594,300)
Cash flows from investing activities: Purchases of investment securities, net Purchases of property and equipment	1,996,700 (525,100)	(234,400)
Net cash used in investing activities	1,471,600	(234,400)
Cash flows from financing activities: Principal payments on capital leases Issuance of common stock	(19,500) 177,200	26,300
Net cash provided by financing activities	157,700	26,300
Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period	(963,400) 5,049,200	(2,802,400) 14,265,800
Cash and cash equivalents at end of period	\$ 4,085,800	\$ 11,463,400

See accompanying notes to financial statements. $</{\rm TABLE>}$

MICROVISION, INC.

Statement of Comprehensive Income

30,	Three months ended June 30,		Six Months E	Six Months Ended June	
	1998	1997	1998		
1997					
<\$>	<c></c>	<c></c>	<c></c>	<c></c>	
Net loss (2,334,100) Other comprehensive loss: Unrealized loss on investment securities	\$ (2,143,200)	\$ (1,175,400)	\$ (3,359,700)	Ş	
available-for-sale	(100)	-	(3,500)		
Comprehensive loss (2,334,100)	\$ (2,143,300)	\$ (1,175,400)	\$ (3,363,200)	Ş	
	===========				

See accompanying notes to financial statements.

</TABLE>

6

MICROVISION, INC. Notes to Financial Statements June 30, 1998

Management's Statement

The accompanying unaudited financial statements of Microvision, Inc. (the "Company") at June 30, 1998 and December 31, 1997 and for the periods then ended have been prepared in accordance with generally accepted accounting principles for interim financial information on a basis consistent with the audited financial statements of the Company for the twelve month period ended December 31, 1997. These statements include all adjustments (consisting only of normal recurring accruals) that, in the opinion of the Company's management, are necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. The interim results are not necessarily indicative of results that may be expected for a full year and should be read in conjunction with MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS set forth herein and with the Company's audited financial statements for the year ended December 31, 1997, which are included in the Company's Annual Report on Form 10-KSB as filed with the Securities and Exchange Commission.

Computation of Net Loss Per Share

Net loss per share and net loss per share assuming dilution information is computed using the weighted average number of shares of common stock outstanding during each period in which the Company reports a loss. Common equivalent shares issuable upon the exercise of outstanding options and warrants to purchase shares of the Company's common stock (using the treasury stock method) are not included in the calculation of the net loss per share and net loss per share assuming dilution because the effect of their inclusion is anti-dilutive.

7

Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Preliminary Note Regarding Forward-Looking Statements The information set forth in this Item 2 contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements may include, but are not limited to, projections of revenues, income, or loss, capital expenditures, plans for product development and cooperative arrangements, future operations, financing needs or plans of the Company, as well as assumptions relating to the foregoing. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Such statements are inherently subject to risks and uncertainties as further described herein and in the "Considerations Related to the Company's Business" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 1997, as filed with the Securities and Exchange Commission. The Company's actual results may differ materially from the results projected in the forward-looking statements.

Overview

The Company commenced operations in May 1993 to develop and commercialize technology for displaying images and information onto the retina of the viewer's eye. In 1993, the Company acquired an exclusive license (the "Exclusive License") to the Virtual Retinal Display(TM) technology ("VRD"(TM)) from the University of Washington ("UW") and entered into a research agreement (the "Research Agreement") with the University of Washington to further develop the $\ensuremath{\mathsf{VRD}}$ technology. The Company was in the development stage as of and for the period ended December 31, 1996. In connection with its development activities, the Company incurred costs to incorporate and establish its business activities as well as develop and market VRD technology. As of December 31, 1997, the Company was no longer considered a development stage enterprise. Since the completion of its initial public offering in August 1996, the Company also has established and equipped its own in-house laboratory for the continuing development of the VRD technology and has transferred the core research and development work from the University of Washington's Human Interface Technology Lab to the Company. The Company has incurred substantial losses since its inception and expects to continue to incur significant operating losses over the next several years.

The Company's objective is to be a leading provider of personal display products and imaging technology in a broad range of professional and consumer applications. The Company expects to achieve this objective and to generate revenues through a combination of the following activities: technology licensing to original equipment manufacturers ("OEMs") of consumer electronics products; provision of engineering services associated with cooperative product development arrangements and research contracts; and the manufacture and sale of high-performance personal display products to professional users, directly, and through OEMs and through joint ventures.

8

The Company is in discussions with systems and equipment manufacturers in the defense and wireless communications, computing, and commercial and consumer electronics industries. The Company expects to work with certain of these manufacturers to develop or co-develop specific products that the Company believes to be the most commercially viable.

To date, the Company's revenues have been derived generally from development contracts with both commercial and government customers. Revenues from sales of products may not occur for several years.

The Company currently has several prototype versions of the VRD including monochromatic and color portable units and a full-color bench-top model. The Company plans to continue funding prototype and demonstration versions of products incorporating the VRD technology throughout 1998. Future revenues, profits and cash flow, and the Company's ability to achieve its strategic objectives as described herein will depend upon a number of factors, including acceptance of the VRD technology by various industries and OEMs, market acceptance of products incorporating the VRD technology and the technical performance of such products. Additionally, the Company must be able to attract, retain and motivate qualified technical and management personnel and anticipate and adapt to a rapidly changing, competitive market for information display technologies.

Plan of Operation

The Company intends to continue entering into strategic co-development relationships with systems and equipment manufacturers to pursue the development of commercial products incorporating VRD technology. The Company continues to identify, assess and pursue various market and product opportunities available to the Company for the commercialization of the VRD technology and to identify and evaluate potential co-development partners. The Company plans to continue to expand its sales and marketing staff in support of its objective of commercializing the VRD technology.

The Company also plans to continue investing in ongoing innovation and improvements to the VRD technology, including the development of component technology and additional prototypes, as well as design of subsystems and products. The Company has established, staffed, and equipped an in-house laboratory to support VRD technology development and product development engineering associated with current cooperative development projects and future cooperative development projects, which the Company expects to receive. The Company plans to continue hiring technical personnel to achieve the Company's technology development objectives and to continue performing on the Company's development contracts.

Results of Operations

The Company's revenues have been derived generally from development contracts with both commercial and government customers. As of June 30, 1998, the Company had an accumulated

9

deficit since inception of \$18.9 million. The Company expects to continue and to increase expenditures in research and development as well as in sales, marketing and administration as it continues to focus its efforts on further development and refinement of the VRD technology and as it continues to pursue commercialization of the VRD technology.

THREE MONTHS ENDED JUNE 30, 1998 COMPARED TO THREE MONTHS ENDED JUNE 30, 1997

Revenue in the three months ended June 30, 1998 increased \$1,953,700 to \$2,055,900 or 1,912% from \$102,200 in the comparable period in 1997. The revenue for the period ended June 30, 1998 was derived from contracts into which the Company entered during both 1997 and the current year.

Research and development expenses in the three months ended June 30, 1998 increased \$1,992,800 or 213% to \$2,926,500 from \$933,700 in the comparable period in 1997. In the period ended June 30, 1997, the Company made a payment of \$320,800 to the University of Washington pursuant to the Research Agreement. The balance of the expenses of \$2,926,500 and \$612,900 in the periods ended June 30, 1998 and 1997, respectively, were incurred directly by the Company in part to further develop the VRD technology.

The increase in research and development expenses of \$1,992,800 for the quarter ended June 30, 1998 over the comparable period in 1997 reflects continued implementation of the Company's operating plan, which calls for building its technical staff, supporting activities to further develop the Company's technology, establishing and equipping its own in-house laboratories, and performing work in support of the Company's sales and marketing activities related to the commercialization of the VRD technology. The increase also includes increased costs incurred in the performance of contracts.

In 1997, the Company made the final payment due under its Research Agreement with the University of Washington, which resulted in the Company now having paid in full the \$5.1 million license fee due under its exclusive license for the VRD technology. In September 1997, the Company and the UW agreed to extend the term of the Research Agreement from October 31, 1997 to March 31, 1998 at no additional cost to the Company. In March 1998, the Company and the UW agreed to extend the term of the Research Agreement from March 31, 1998 to December 31, 1998, at no additional cost to the Company. The extension is expected to enable the UW to complete performance of certain research activities under the Research Agreement.

The Company expects its research and development expenses to increase in the future over prior periods. In addition to costs associated with performing on contracts, the Company plans to continue to build its technical staff and research capabilities in support of current and future contracts, to expand internal research and development activities, to increase technical support of sales and marketing efforts, and to prepare for performing on future contracts relating to the commercialization of the VRD technology.

Marketing, general and administrative expenses in the three months ended June 30, 1998 $\,$

10

increased \$618,900 or 85% to \$1,345,800 from \$726,900 in the comparable period in 1997. The increase includes increased aggregate compensation and associated support costs for employees including those employed at June 30, 1997 and those hired subsequent to that date in sales and marketing and in administration. The Company expects marketing, general and administrative expenses to increase in future periods as the Company makes additional investments in sales and marketing activities to promote its VRD technology and anticipated products and as it adds to its sales and marketing and administrative staff and increases the level of corporate and administrative activity.

Other income for the three months ended June 30, 1997 was \$222,500, which resulted from the reduction of an accrued liability for litigation upon settlement of the matter at a lesser amount than the established reserve.

Net interest income in the three months ended June 30, 1998 was \$73,200 compared to net interest income of \$160,500 in the comparable period of 1997. This decrease was due principally to lower average cash balances in the three months ended June 30, 1998, compared to the same period in 1997, representing the remaining net proceeds received by the Company from its initial public offering in August 1996.

During the quarter ended June 30, 1998, the Company announced that it had

entered into two development contracts. In May, the Company announced the receipt of a Phase II Small Business Innovation Research (SBIR) contract from the Department of Defense for the development of a High Fidelity Head Mounted Display (HMD). The HDTV quality HMD is for use in flight simulators for training military pilots. The \$1.1 million award combines funding from the Department of Defense and Saab AB and Ericsson-Saab Avionics, Microvision's commercial partner in the "fast-track" program. In June, the Company announced that it had received another Phase II SBIR contract totaling approximately \$583,000 from the U.S. Air Force to develop a wide field-of-view head-worn display system. Microvision's VRD technology is expected to enable Command, Control, Communications, Computers & Intelligence personnel to view large amounts of mission- and situation-critical data through a light-weight eyewear display system, resembling glasses, during both wartime conditions and training sessions.

The Company also made important deliveries during the quarter. In April, the Company delivered an advanced helmet-mounted display to a large, international avionics company. More recently the Company delivered its second HMD to Saab-AB and Ericsson Saab Avionics, pursuant to its development agreement with those companies.

The Company also continues to increase its intellectual property (IP) portfolio both related to its proprietary VRD technology and in other technologies. Rapid growth of the IP portfolio is a part of the Company's marketing strategy and aggressive micro-display technology research and development efforts.

In April the Company announced that it had expanded its IP portfolio with the issuance of four new patents. Also, the number of pending applications has increased to twelve. In excess of twenty patent applications are expected to be filed during 1998.

11

Subsequent to the end of the quarter, the Company announced that it had acquired the rights to three patents and eleven pending patents relating to the design and fabrication of a micro miniature scanning device that can be manufactured using semi-conductor fabrication techniques. The Company also demonstrated the device, which represents a breakthrough for a wide variety of next generation display and imaging products. The development is significant because of the degree of system miniaturization it enables, and because it has the potential to afford significant production economies through the use of highly automated batch fabrication techniques.

SIX MONTHS ENDED JUNE 30, 1998 COMPARED TO SIX MONTHS ENDED JUNE 30, 1997

Revenue in the six months ended June 30, 1998 increased by \$3,661,900 or 3,583% to \$3,764,100 from \$102,200 in the comparable period in 1997. The revenue for the period ended June 30, 1998 was derived from contracts into which the Company entered during both 1997 and the current period.

Research and development expenses in the six months ended June 30, 1998 increased by \$3,202,400 or 202% to \$4,785,800 from \$1,583,400 in the comparable period in 1997. In the period ended June 30, 1997, the Company made payments totaling \$641,600 to the University of Washington pursuant to the Research Agreement. The balance of the expenses of \$4,785,800 and \$941,800 in the periods ended June 30, 1998 and 1997, respectively, were incurred directly by the Company in part to further develop the VRD technology.

The increase in research and development expenses of \$3,202,400 for the six months ended June 30, 1998 over the comparable period in 1997 reflects continued implementation of the Company's operating plan, which calls for building its technical staff, supporting activities to further develop the Company's technology, establishing and equipping its own in-house laboratories, and performing work in support of the Company's sales and marketing activities related to the commercialization of the VRD technology. The increase also includes increased costs incurred in the performance of contracts.

The Company expects its research and development expenses to increase in the future over prior periods. In addition to costs associated with performing on contracts, the Company plans to continue to build its technical staff and research capabilities in support of current and future contracts, to expand internal research and development activities, to increase technical support of sales and marketing efforts, and to prepare for performing on future contracts relating to the commercialization of the VRD technology.

Marketing, general and administrative expenses in the six months ended June 30, 1998 increased \$1,107,400 or 79% to \$2,514,600 from \$1,407,200 in the comparable period in 1997. The increase includes increased aggregate compensation and associated support costs for employees including those employed at June 30, 1997 and those hired subsequent to that date in sales and marketing and in administration. The Company expects marketing, general and

administrative expenses to increase in future periods as the Company makes additional investments in sales and marketing activities to promote its VRD technology and anticipated products and as it adds to its sales and marketing and administrative staff and increases the level of corporate and administrative activity.

Other income for the six months ended June 30, 1997 was \$222,500, which resulted from the reduction of an accrued liability for litigation upon settlement of the matter at a lesser amount than the established reserve.

Net interest income in the six months ended June 30, 1998 was \$176,600 compared to net interest income of \$331,800 in the comparable period of 1997. This decrease was due principally to lower average cash balances in the six months ended June 30, 1998, as compared to the same period in 1997, representing the remaining net proceeds received by the Company from its initial public offering in August 1996.

LIQUIDITY AND CAPITAL RESOURCES

From inception through July 1996, the Company financed its operations primarily through private equity sales and a private placement of convertible subordinated notes. In August 1996, the Company completed its initial public offering of 2,250,000 units, each unit consisting of one share of common stock and one five-year redeemable warrant to purchase one share of common stock at \$12.00 per share. The Company received net proceeds from the offering of approximately \$15.5 million after deducting underwriting discounts and offering expenses.

At June 30, 1998 the Company had \$5.9 million in combined cash, cash equivalents and investment securities available-for-sale. The Company believes that these funds together with revenue earned on contracts will satisfy its budgeted cash requirements for at least the next twelve months based on the Company's current operating plan. Actual expenses, however, may exceed the amounts budgeted, and will depend, in part, on the opportunities that arise for commercialization of the VRD technology. The Company may require additional capital earlier to develop products, to respond to competitive pressures, to meet unanticipated development difficulties, or for other working capital purposes. There can be no assurance that any additional financing will be available when needed or, if available, on terms satisfactory to the Company.

Subsequent to the end of the quarter, the Company entered into a letter of intent to lease office space to house the company's operations over the longer term by providing space to accommodate the Company's planned growth in staff and lab requirements. Under the terms of the proposed lease, the Company would lease between 92,000 square feet and 101,000 square feet in two commitments over the first four years of the seven year term of the lease. The proposed lease is a triple net lease. Based on the initial commitment of approximately 67,500 square feet, the base rent expense during the first year of occupancy is estimated at approximately \$861,000, increasing to approximately \$931,000 in the second year. The proposed lease terms include an option for the Company to extend the initial lease term for one period of five years as well as other options to acquire additional space should the need arise. Occupancy is expected during the first quarter of 1999.

The Company's future expenditures and capital requirements will depend on numerous factors, including the progress of its research and development program, the progress in its

13

commercialization activities, the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, competing technological and market developments and the ability of the Company to establish cooperative development, joint venture and licensing arrangements. If the Company is successful in establishing co-development and joint venture arrangements, it is expected that the Company's partners would fund certain non-recurring engineering costs for product development. Nevertheless, the Company expects its cash requirements to increase significantly each year as it expands its operations.

The Company is currently working to resolve the potential impact of the year 2000 on the processing of date-sensitive information by the Company's computerized information systems. The year 2000 problem is the result of computer programs being written using two digits (rather than four) to define the applicable year. Any of the Company's programs that have time-sensitive software may recognize a date using "00" as the year 1900 rather than the year 2000, which could result in miscalculation or system failures. Based on preliminary information, costs of addressing potential problems are not currently expected to have a material adverse impact on the Company's financial position, results of operations or cash flows in future periods. However, if the Company, its customers or vendors are unable to resolve such processing issues in a timely manner, it could result in a material financial risk. Accordingly, the Company plans to devote the necessary resources to resolve all significant year 2000 issues in a timely manner.

Part II OTHER INFORMATION

Item 1. Legal Proceedings

The Company is not a party to, nor is its property subject to, any material pending legal proceeding.

Item 2. Changes In Securities and Use of Proceeds

In August 1996 the Company issued certain underwriters' warrants to marion bass securities corporation ("Bass") as partial underwriting compensation in connection with the Company's initial public offering ("Offering"). Bass transferred certain of the underwriters' warrants to Burt Davis, an employee of Bass, subsequent to the closing of the Offering. On January 23, 1998, the Company issued 12,489 shares of Common Stock and warrants to purchase 12,489 shares of Common Stock and warrants acquired by Mr. Isley from Mr. Davis in a private transaction. On May 27, 1998, the Company issued 5,187 shares of Common Stock and warrants to purchase 5,187 shares of Common Stock to Bass upon the "cashless exercise" of underwriters' warrants.

On May 27, 1998, the Company also issued 14,008 shares of Common Stock and warrants to purchase 14,008 shares of Common Stock to Mr. Isley upon the "cashless exercise" of certain private warrants issued to Mr. Davis in consideration of pre-Offering financial consulting services provided to the Company. Mr. Isley acquired such private warrants from Mr. Davis in a private transaction.

The Company's sale of the shares of Common Stock and Common Stock purchase warrants to Bass and to Mr. Isley were exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 4(2) thereof, based on the nature of the offering and status of the offerees.

Item 3. Defaults upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other Information

None

- Item 6. Exhibits and Reports on Form 8-K
 - a. Exhibits
 - 3.1 Amended and Restated Bylaws*
 - 10.1 Form of office lease between the City of Seattle and Microvision, Inc. dated April 29, 1998 relating to Suite 280 of office building located at 2203 Airport Way South, Seattle, Washington 98134*
 - 10.2 Form of Executive Stock Loan Agreement*
 - 11. Computation of Net Loss Per Share and Net Loss Per Share Assuming Dilution*
 - 27. Financial Data Schedule

- * Incorporated by reference to the Company's Form 10-QSB filed on August 14, 1998.
- b. Reports on Form 8-K

During the quarterly period ended March 31, 1998, the Company filed no Current Reports on Form 8-K.

15

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 27, 1998	RICHARD F. RUTKOWSKI
	Richard F. Rutkowski President, Chief Executive Officer (Principal Executive Officer)
Date: August 27, 1998	RICHARD A. RAISIG
	Richard A. Raisig Chief Financial Officer (Principal Financial and Accounting Officer)

16

EXHIBIT INDEX

Exhibit Number 	Description
3.1	Amended and Restated Bylaws*
10.1	Form of office lease between the City of Seattle and Microvision, Inc. dated April 29, 1998 relating to Suite 280 of office building located at 2203 Airport Way South, Seattle, Washington 98134*
10.2	Form of Executive Stock Loan Agreement*
11.	Computation of Net Loss Per Share and Net Loss Per Share Assuming $\ensuremath{Dilution}^\star$
27.	Financial Data Schedule

* Incorporated by reference to the Company's Form 10-QSB filed on August 14, 1998.

<TABLE> <S> <C>

<ARTICLE> 5 <LEGEND> This Schedule contains summary financial information extracted from the unaudited financial statements of Microvision, Inc., for the three month period ended June 30, 1998 and is qualified in its entirety by reference to such financial statements. </LEGEND>

<s></s>	<c></c>	
<period-type></period-type>	3-MOS	
<fiscal-year-end></fiscal-year-end>		DEC-31-1997
<period-end></period-end>		JUN-30-1998
<cash></cash>		4,085,800
<securities></securities>		1,795,300
<receivables></receivables>		1,342,900
<allowances></allowances>		(12,000)
<inventory></inventory>		0
<current-assets></current-assets>		8,026,900
<pp&e></pp&e>		1,706,200
<depreciation></depreciation>		(379,100)
<total-assets></total-assets>		9,398,100
<current-liabilities></current-liabilities>		2,877,700
<bonds></bonds>		224,300
<preferred-mandatory></preferred-mandatory>		0
<preferred></preferred>		0
<common></common>		25,553,300
<other-se></other-se>		(19,257,200)
<total-liability-and-equity></total-liability-and-equity>		9,398,100
<sales></sales>		0
<total-revenues></total-revenues>		3,764,100
<cgs></cgs>		0
<total-costs></total-costs>		0
<other-expenses></other-expenses>		7,288,400
<loss-provision></loss-provision>		12,000
<interest-expense></interest-expense>		(12,900)
<income-pretax></income-pretax>		(3,359,700)
<income-tax></income-tax>		0
<income-continuing></income-continuing>		(3,359,700)
<discontinued></discontinued>		0
<extraordinary></extraordinary>		0
<changes></changes>		0
<net-income></net-income>		(3,359,700)
<eps-primary></eps-primary>		(.56)
<eps-diluted></eps-diluted>		(.56)
		(100)

</TABLE>